Kerbside

The recommendations provided in this column are taken from various market sources such as brokers, analysts, dealers and investment strategists, etc. These recommendations may not be backed by strong fundamentals. Therefore we advise readers to use their own discretion before investing in these recommendation 

REVENUE GROWTH 

Havells 

BSE Code: 517354
CMP: Rs 701.45 


Havells India is engaged in manufacturing switchgears, cables and wires, lighting and fixtures and electric consumer durables (ECDs). Havells surprised on the positive side by reporting strong revenue growth, driven by ECDs, cables and wires and lighting segments. The Lloyd and switchgear segments were also not far behind and have reported health growth rates. However, factors such as volatility in commodity prices, currency headwinds and delay in passing increased input costs continued to impact margins and the strong revenue growth was partially offset by lower margins. The management expects margins to improve during Q4 in line with the yearly average. The product expansion in ECD segment along with Lloyd RAC plant are likely to benefit the stock in the coming quarters. 

VOLUME JUMP 

Mphasis 

BSE Code: 526299
CMP: Rs 970.65 

There is a buzz in the markets that HNIs and traders have been stacking up shares of Mphasis over the last week or so. The stock has seen its trading volume jump by over 25 per cent as on January 29 as compared to its average of 10 days. The chatter is on the street that this stock is headed northwards as analyst expect Mphasis business from Blackstone portfolio has the potential to grow faster than its core direct business and risk-takers can go for this scrip and hope to make some quick buck 

HEALTHY RESULTS 

Praj Industries 

BSE Code: 522205
CMP: Rs 129.05 


The company has announced a healthy set of results during the Q3FY19, with revenues going up by 33 per cent and PAT moving up by 190 per cent as compared to the corresponding quarter of the last year. The performance was driven by strong traction across bio-energy and engineering business segments. As per the management, the visibility of business is steadily improving in the light of continued mandate intensity in domestic and international markets as well as favourable customer response to a wider bouquet of offerings. Those with high risk appetite can take their bets on this scrip to make some quick gains. 

AND FINALLY.. 

Pfizer 

BSE Code: 500680
CMP: Rs 2919.90 


The company is the third-largest pharmaceutical multinational company in the country. It has a portfolio of over 150 products across 15 therapeutic areas. Its top brands include Prevenar 13, Lyrica, Eliquis, Enbrel, Becosules, Gelusil and Corex range of products. The company was awarded the FICCI SEDF (Socio Economic Development Foundation) Certificate of Commendation for its social responsibility efforts.Pfizer has won several awards including that for the multinational pharmaceutical company of the year and the most respected MNC. As per the chartists, the stock is placed around its crucial long term support and it may resume its uptrend. Do not miss this golden opportunity. 

Rate this article:
No rating
Comments are only visible to subscribers.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR